A carregar...
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action
Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, is approved worldwide for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH-LUTS). The purpose of this narrative review is to summarize the clinical data on tadalafil 5 mg once-daily, primarily focusin...
Na minha lista:
| Publicado no: | Ther Adv Urol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4549700/ https://ncbi.nlm.nih.gov/pubmed/26425140 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287215589238 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|